Advertisement

---

NOVARTIS ONCOLOGY

Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

[2013-06-02] - -- A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients(1)
-- First Phase III study showing that inhibition of HER2 positive receptor and mTOR provides significant benefit in HER2 positive advanced breast cancer(1)
-- Everolimus is currently approved as Afinitor in more than 65 countries for the treatment of advanced HR+/HER2 negative breast cancer(2)


Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement

[2013-05-21] - - Breast cancer is the most common cancer in women worldwide, yet survey confirms many women living with advanced form of disease feel isolated(1),(2)
- Three in four women surveyed say they actively seek out information(2), yet more than half say the information they find does not address their needs(2)
- "Count Us, Know Us, Join Us" survey gives a voice to the 250,000 women living with advanced breast cancer around the world(3),(4)


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers